Phonak Unveils Infinio Portfolio with AI-Driven Speech Clarity in Audéo Sphere
Phonak, a Sonova brand, is excited to introduce the new Infinio hearing aid portfolio, featuring the groundbreaking Audéo Sphere Infinio. This hearing aid is the world’s first to use a dedicated real-time AI chip specifically designed for speech-from-noise separation. Addressing…
Hims & Hers Reports Q2 2024 Financials
Hims & Hers Health, Inc. (NYSE: HIMS), a leading health and wellness platform, has released its financial results for the second quarter ended June 30, 2024. The details are available in the shareholder letter posted at investors.hims.com. Hims & Hers…
Concentric Analgesics Reports Two Weeks of Pain Relief and Early Opioid Cessation in Surgical Procedures
Concentric Analgesics, Inc., a clinical-stage biopharmaceutical firm specializing in innovative non-opioid pain treatments, has unveiled new positive clinical data for vocacapsaicin, its leading product candidate for managing postsurgical pain. The data will be presented in a poster session at the…
Enanta Pharmaceuticals Reports Q3 Fiscal Results
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotech firm focused on developing small molecule drugs for virology and immunology, has reported its financial results for the fiscal third quarter ending June 30, 2024. Recent Business Highlights: Clinical and Research Updates: Upcoming…
Delcath Systems Reports Q2 2024 Results and Key Updates
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company specializing in treating primary and metastatic liver cancers, has announced its financial results and business highlights for the second quarter ended June 30, 2024. Recent Business Highlights “We are thrilled with…
CUSM Gets Bank of America Grant to Improve Rural Healthcare Access
California University of Science and Medicine (CUSM) has announced a grant from Bank of America to enhance healthcare in rural Inland Empire communities. The funding will support CUSM’s initiative to provide simulation-based clinical equipment and training to healthcare facilities and…
Tris Pharma Reveals Strong Safety and Efficacy Data for Cebranopadol, a New Pain Therapy
Tris Pharma, Inc., a biopharmaceutical company specializing in ADHD, pain, addiction, and neurological disorders, has announced new clinical data showcasing that cebranopadol, a dual nociceptin/orphanin FQ peptide (NOP) receptor and µ-opioid peptide (MOP) receptor agonist, causes significantly less respiratory depression…
Advanced Sterilization Products and PENTAX Medical Gain FDA Clearance for New Duodenoscope Sterilization Cycle
Advanced Sterilization Products (ASP), a division of Fortive (NYSE: FTV), and PENTAX Medical, a division of HOYA, are excited to announce FDA clearance for the new ULTRA GI™ Cycle. This innovative cycle is integrated into the STERRAD™ 100NX Sterilizer with…
Eyedaptic Launches EYE6 with Ivy: AI-Powered Visual Assistant for Macular Degeneration
Eyedaptic, a leader in vision-enhancement technology, has introduced the EYE6 with Ivy, an advanced wearable vision aid featuring an AI-powered visual assistant. This next-generation smart glasses product is designed to assist individuals with age-related macular degeneration (AMD) and other retinal…
Alzamend Neuro and Mass General Launch Phase II Trial for AL001 in Alzheimer’s Disease
Alzamend Neuro, Inc. (Nasdaq: ALZN), a clinical-stage biopharmaceutical company focused on developing treatments for Alzheimer’s disease, bipolar disorder, major depressive disorder, and post-traumatic stress disorder, has announced a partnership with Massachusetts General Hospital (Mass General). Mass General will serve as…
Mettler-Toledo Reports Q2 2024 Results
Mettler-Toledo International Inc. (NYSE: MTD) has released its financial results for the second quarter of 2024. Key highlights include: Second Quarter Highlights Management Commentary Patrick Kaltenbach, President and CEO, commented, “Our team delivered strong Laboratory sales growth in Europe and…
Amylyx Pharmaceuticals Gets EU Orphan Drug Status for AMX0035 in Wolfram Syndrome
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) has announced that the European Commission has granted Orphan Drug Designation to AMX0035, its proprietary fixed-dose combination of sodium phenylbutyrate (PB) and taurursodiol (TURSO), for treating Wolfram syndrome. This designation follows a positive opinion from…